Home>Topics>Stocks>Holly Energy Partners

Holly Energy Partners HEP

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Headlines
    1. The Hidden Side Of Sovaldi's Untapped Markets: Gilead's Rise Is Certain


      Mon, 30 Jun 2014

      relapse rate. Then came Gilead Sciences' ( GILD ) Sovaldi, which had relatively fewer side effects and the ability to eradicate Hep C 4 times faster than leading medications. Boosting Sovaldi's realized efficacy was that fact that the regimen involved taking

    2. Analyzing The Hepatitis C Market Size: Why It May Have Bullish Implications For Gilead


      Mon, 23 Jun 2014

      regimens to cure a form of viral hepatitis, namely hepatitis C (" hep C" herein). The two products that when combined in one treatment ..... Olysio with Sovaldi is expected to diminish when Gilead's next hep C blockbuster enters the market, likely in October. This is

    3. Sovaldi And Drug Pricing: The United States Of Saps


      Thu, 19 Jun 2014

      been rising in recent years on heightened expectations of the hep -C drug, and in the chart below one sees the increasing forward ..... there are enough well-insured (including by the government) hep -C patients to propel and sustain sales of all three companies

    4. What Is Next For The Hepatitis C Space?


      Fri, 13 Jun 2014

      hepatitis C market has come on investor's radar in a big way over the last few months. Gilead Sciences ( GILD ) launched its Hep C drug, Sovaldi, in the first quarter. The drug carries a huge price tag for its 12 week treatment program but cures what

    5. Conatus benefits from Hep C drug excitement


      Thu, 12 Jun 2014

      the rising tide of investor enthusiasm for hepatitis drugs led by the wildly successful launch of Gilead's ( GILD +0.2% ) Hep C treatment Sovaldi. Yesterday, shares popped 57% on a 19-fold surge in volume. The company's lead product is emricasan

    6. Oregon Health Plan says no to unlimited access to pricey Hep C drugs


      Thu, 12 Jun 2014

      becoming more and more popular among clinicians, costs $150,000 per regimen. Covering a third of the 7,000 OHP members with Hep C for Sovaldi alone ($84,000/regimen) would cost $196M. This would double its system-wide drug spending. Last year

    7. New Morningstar Analyst Report for Holly Energy Partners LP

      Stock Reports

      Thu, 1 May 2014

      less flat demand. Holly Energy Partners operates a network ..... HollyFrontier, formed HEP in 2004 to acquire ..... strategic relationship. HEP also faces pipeline ..... value estimate for Holly Energy Partners to $34 per unit from ..... yield of 5.9%. In HEP 's domestic pipelines

    8. Crumbling Boardwalk Empire Doesn't Shake MLP Foundation


      Wed, 12 Mar 2014

      our MLP coverage, we rate only three other stocks as low uncertainty-- Magellan Midstream Partners MMP, Holly Energy Partners HEP , and Spectra Energy Partners. We continue to believe that these three partnerships exhibit stable, predictable

    9. New Morningstar Analyst Report for HollyFrontier Corp

      Stock Reports

      Tue, 28 Jan 2014

      board and chairman and CEO of Holly Energy Partners L.P. Mike Jennings, CEO ..... has a 39% ownership stake in Holly Energy Partners , which owns and operates petroleum ..... the value in the ownership of HEP . Our fair value estimate implies

    10. Holly Energy Expects Lower Crude Volumes from HollyFrontier’s Navajo Refinery


      Mon, 11 Nov 2013

      a concern for Holly Energy Partners ’ own crude throughput ..... volume impact for Holly Energy Partners , note that HEP saw about 173 ..... flows through to HEP with lower pipeline ..... highlight that Holly Energy Partners also has very

    « Prev12345Next »
    Content Partners